Citius Oncology Past Earnings Performance
Past criteria checks 0/6
Citius Oncology's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-21.4%
Earnings growth rate
-21.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -114.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Citius Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -20 | 14 | 5 |
| 31 Mar 24 | 0 | -17 | 12 | 5 |
| 31 Dec 23 | 0 | -16 | 11 | 4 |
| 30 Sep 23 | 0 | -13 | 8 | 4 |
| 30 Jun 23 | 0 | -16 | 6 | 8 |
Quality Earnings: CTOR is currently unprofitable.
Growing Profit Margin: CTOR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CTOR's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CTOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: CTOR has a negative Return on Equity (-114.64%), as it is currently unprofitable.